Literature DB >> 26321154

HPV vaccines: their pathology-based discovery, benefits, and adverse effects.

Alcina F Nicol1, Cecilia V de Andrade2, Fabio B Russomano2, Luana S L Rodrigues3, Nathalia S Oliveira1, David William Provance4, Gerard J Nuovo5.   

Abstract

The discovery of the human papillomavirus (HPV) vaccine illustrates the power of in situ-based pathologic analysis in better understanding and curing diseases. The 2 available HPV vaccines have markedly reduced the incidence of cervical intraepithelial neoplasias, genital warts, and cervical cancer throughout the world. Concerns about HPV vaccine safety have led some physicians, health care officials, and parents to refuse providing the recommended vaccination to the target population. The aims of the study were to discuss the discovery of HPV vaccine and review scientific data related to measurable outcomes from the use of HPV vaccines. The strong type-specific immunity against HPV in humans has been known for more than 25 years. Multiple studies confirm the positive risk benefit of HPV vaccination with minimal documented adverse effects. The most common adverse effect, injection site pain, occurred in about 10% of girls and was less than the rate reported for other vaccines. Use of HPV vaccine should be expanded into more diverse populations, mainly in low-resource settings.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse events; Cervical cancer; HPV vaccine; Human papillomavirus; Vaccination

Mesh:

Substances:

Year:  2015        PMID: 26321154     DOI: 10.1016/j.anndiagpath.2015.07.008

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  10 in total

Review 1.  Vaccine and immune cell therapy in non-small cell lung cancer.

Authors:  Helena Oliveres; Christian Caglevic; Francesco Passiglia; Simona Taverna; Evelien Smits; Christian Rolfo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

2.  A Novel In Vivo Model of Laryngeal Papillomavirus-Associated Disease Using Mus musculus Papillomavirus.

Authors:  Renee E King; Andrea Bilger; Josef Rademacher; Ella T Ward-Shaw; Rong Hu; Paul F Lambert; Susan L Thibeault
Journal:  Viruses       Date:  2022-05-08       Impact factor: 5.818

Review 3.  Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature.

Authors:  Beniamino Palmieri; Dimitri Poddighe; Maria Vadalà; Carmen Laurino; Carla Carnovale; Emilio Clementi
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay.

Authors:  Mart Toots; Mart Ustav; Andres Männik; Karl Mumm; Kaido Tämm; Tarmo Tamm; Ene Ustav; Mart Ustav
Journal:  PLoS Pathog       Date:  2017-02-09       Impact factor: 6.823

5.  Primary care pediatricians' attitudes and practice towards HPV vaccination: A nationwide survey in Italy.

Authors:  Francesco Napolitano; Monica Navaro; Luigi Vezzosi; Gabriella Santagati; Italo Francesco Angelillo
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

6.  The Efficacy and Safety of Continuous Intravenous Endostar Treatment Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Squamous Cell Carcinoma: A Randomized Controlled Trial.

Authors:  Hang Shu; Yaqin Dong; Zhonghua Xu; Weiwei Luo; Lei Xu; Haochen Zhu; Linghui Cheng; Yin Lv
Journal:  Front Oncol       Date:  2021-08-13       Impact factor: 6.244

Review 7.  Health Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated Malignancies.

Authors:  Amira H Bakir; Martin Skarzynski
Journal:  Front Public Health       Date:  2015-12-17

8.  High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.

Authors:  Jian Guan; Stephanie M Bywaters; Sarah A Brendle; Robert E Ashley; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  Viruses       Date:  2017-12-06       Impact factor: 5.048

9.  The molecular biology and HPV drug responsiveness of cynomolgus macaque papillomaviruses support their use in the development of a relevant in vivo model for antiviral drug testing.

Authors:  Eva-Maria Tombak; Andres Männik; Robert D Burk; Roger Le Grand; Ene Ustav; Mart Ustav
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

Review 10.  Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches.

Authors:  Kamya Sankar; Sunitha Nagrath; Nithya Ramnath
Journal:  Cancers (Basel)       Date:  2021-03-23       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.